GFH375 with cetuximab or chemo for KRAS G12D cancers
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a new drug called GFH375 combined with either cetuximab or chemotherapy for people with advanced solid tumors that have a specific genetic change called KRAS G12D. It's for those whose cancer has worsened after other treatments or who can't have standard therapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old (75 or younger if joining certain treatment groups).
- Your cancer must be advanced (spread or cannot be removed) and have the KRAS G12D mutation.
- You must have tried standard treatments that didn't work or aren't suitable.
- You need to have at least one tumor that can be measured on scans.
- You must be in fairly good health (able to care for yourself).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called GFH276 combined with either cetuximab or chemotherapy for people with certain cancers that have a specific genetic change called a RAS mutation. It focuses on solid tumors and pancreatic cancer (PDAC) and aims to see if the combination is safe and effective.
This trial tests a new drug called GFH276 for people with advanced solid tumors that have a RAS mutation. It aims to see if the drug is safe and effective against these tumors.
This study tests a new targeted drug, GFH375, against standard chemotherapy for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the new drug works better and has fewer side effects.
This trial tests a new oral medication (GFH375) for people with advanced solid tumors that have a specific KRAS G12D mutation. The goal is to see if the drug can shrink tumors or slow cancer growth.
This trial tests a new drug called GFH375, either alone or combined with other treatments, for advanced non-small cell lung cancer that has a specific KRAS G12D mutation. The goal is to see if this targeted approach can slow or shrink your cancer better than standard treatments.
This trial tests whether combining two experimental drugs (GFH375 with GFS202A or GFH276) works better than one drug alone for people with advanced pancreatic cancer that has a specific genetic change called KRAS G12D. It may offer a new option for those who have already tried other treatments.
Hear when a new PDAC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.